

Transparency notifications received from François Rieger, Véronique Pomi, Capital Grand Est, FA DIESE 3 and CPH Banque

Article 14 of the Law of 2 May 2007 on disclosure of major holdings

Mont-Saint-Guibert, Belgium, November 21, 2022, 7am CEST – [BIOSENIC](#) (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and organ/function repair, today announces that it has received transparency notifications from François Rieger, Véronique Pomi, Capital Grand Est, FA DIESE 3 and CPH Banque. The notifications details can be found below and can be consulted on the website of BioSenic, under the heading “*Major shareholders & transparency notices*”.

The transparency notification indicates that the shareholdings held by **François Rieger** have crossed above the threshold of 20% as a result of the issuance of new shares of BioSenic to Medsenic shareholders on 24 October 2022.

The notification received from François Rieger dated 09 November 2022 contains the following information:

- Reason for the notification:
 - *Acquisition or disposal of voting securities or voting rights.*
- Notification by: *A person that notifies alone*
- Person subject to the notification requirement: *François Rieger*
- Transaction date: *24 October 2022*
- Threshold that is crossed: *20%*
- Denominator: *115,132,015*
- Notified details:

| Voting rights | Previous notification | After the transaction | |
|--------------------------|-----------------------|-----------------------|--------------------|
| Holders of voting rights | # of voting rights | # of voting rights | % of voting rights |
| François Rieger | | 26,589,361 | 23.09% |
| Total voting rights | | 26,589,361 | 23.09% |

The notification can be consulted on the website of BioSenic, under the heading “*Major shareholders & transparency notices*”.

The transparency notification indicates that the shareholdings held by **Véronique Pomi** have crossed above the threshold of 10% as a result of the issuance of new shares of BioSenic to Medsenic shareholders on 24 October 2022.

The notification received from Véronique Pomi dated 09 November 2022 contains the following information:

- Reason for the notification:
 - *Acquisition or disposal of voting securities or voting rights.*
- Notification by: *A person that notifies alone*
- Person subject to the notification requirement: *Véronique Pomi*
- Transaction date: *24 October 2022*
- Threshold that is crossed: *10%*
- Denominator: *115,132,015*
- Notified details:

| Voting rights | Previous notification | After the transaction | |
|--------------------------|-----------------------|-----------------------|--------------------|
| Holders of voting rights | # of voting rights | # of voting rights | % of voting rights |
| Véronique Pomi | | 13.306.121 | 11.56% |
| Total voting rights | | 13.306.121 | 11.56% |

The notification can be consulted on the website of BioSenic, under the heading “*Major shareholders & transparency notices*”.

The transparency notification indicates that the shareholdings held by **Capital Grand Est** have crossed above the threshold of 10% as a result of the issuance of new shares of BioSenic to Medsenic shareholders on 24 October 2022.

The notification received from Capital Grand Est SAS dated 10 November 2022 contains the following information:

- Reason for the notification:
 - *Acquisition or disposal of control of an undertaking that holds a participating interest in an issuer.*
- Notification by: *A person that notifies alone*
- Person subject to the notification requirement: *Capital Grand Est, Société par Actions Simplifiée*
- Transaction date: *24 October 2022*
- Threshold that is crossed: *10%*
- Denominator: *115,132,015*
- Notified details:

| Voting rights | Previous notification | After the transaction | |
|--------------------------|-----------------------|-----------------------|--------------------|
| | | # of voting rights | % of voting rights |
| Holders of voting rights | # of voting rights | # of voting rights | % of voting rights |
| Capital Grand Est SAS | | 14,045,094 | 12.20% |
| Total voting rights | | 14,045,094 | 12.20% |

- Full chain of controlled undertakings through which the holding is effectively held: *Capital Grand Est is not under control.*
- Additional information: *Capital Grand Est SAS is the management company that can execute the voting rights as it sees fit in the absence of specific instructions.*

The notification can be consulted on the website of BioSenic, under the heading “*Major shareholders & transparency notices*”.

The transparency notification indicates that the shareholdings held by **FA DIESE 3** have crossed above the threshold of 5% as a result of the issuance of new shares of BioSenic to Medsenic shareholders on 24 October 2022.

The notification received from FA DIESE 3 SAS dated 16 November 2022 contains the following information:

- Reason for the notification:
 - *Acquisition or disposal of control of an undertaking that holds a participating interest in an issuer*
- Notification by: *A person that notifies alone*
- Person subject to the notification requirement: *FA DIESE 3*
- Transaction date: *24 October 2022*
- Threshold that is crossed: *5%*
- Denominator: *115,132,015*
- Notified details:

| Voting rights | Previous notification | After the transaction | |
|--------------------------|-----------------------|-----------------------|--------------------|
| Holders of voting rights | # of voting rights | # of voting rights | % of voting rights |
| FA DIESE 3 SAS | | 6,852,103 | 5,95% |
| Total voting rights | | 6,852,103 | 5,95% |

- Full chain of controlled undertakings through which the holding is effectively held: *FA DIESE 3 is not under control.*

The notification can be consulted on the website of BioSenic, under the heading “*Major shareholders & transparency notices*”.

The transparency notification indicates that the shareholdings held by **CPH Banque** have crossed below the threshold of 5% as a result of the issuance of new shares of BioSenic to Medsenic shareholders on 24 October 2022.

The notification received from CPH Banque dated 07 November 2022 contains the following information:

- Reason for the notification:
 - *Downward crossing of the lowest threshold*
 - *Passive crossing of a threshold*
- Notification by: *A person that notifies alone*
- Person subject to the notification requirement: *CPH Banque*
- Transaction date: *24 October 2022*
- Threshold that is crossed: *5%*
- Denominator: *115,132,015*

The notification can be consulted on the website of BioSenic, under the heading “*Major shareholders & transparency notices*”.

About BioSenic

BioSenic is a leading biotech company specializing in the development of clinical assets issued from: (i), the allogeneic cell therapy platform ALLOB and (ii) the Arsenic TriOxide (ATO) platform. Key target indications for the platforms include Graft versus Host Disease (GvHD), Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial fractures.

Following the merger in October 2022, BioSenic combines the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger also enables Biosenica to add to its innovative cell therapy platform and strong IP for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO.

BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at <http://www.biosenic.com>.

About BioSenic technology platforms

BioSenic's technology is based on:

- 1) *The allogeneic cell and gene therapy platform, developed by Bone Therapeutics with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) that can be stored at the point of use in hospitals. Its current investigational medicinal product, ALLOB, represents a unique, proprietary approach to organ repair and specifically to bone regeneration, by turning undifferentiated stromal cells from healthy donors into bone-forming cells on the site of injury. These cells are produced via a proprietary BioSenic scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental, and should be of value in new indications when cells will be further adapted or transformed with additional targeting properties.*
- 2) *The Arsenic TriOxide (ATO) platform developed by Medsenic. The immunomodulatory properties of ATO have demonstrated a double basic effect on cells of the immune system. The first effect is the increase of the cell oxidative stress in activated B, T or other cells of the innate/adaptative immune system to the point they will enter a cell death program (apoptosis) and be eliminated. The second effect is potent immunomodulatory properties on several pro-inflammatory cytokines involved in inflammatory or autoimmune cell pathways. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. GvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-SCT). GvHD is primarily mediated by the transplanted immune system that can lead to severe multiorgan damage. Medsenic had been successful in a Phase II trial with its intravenous formulation, allowing arsenic trioxide to be granted an orphan drug designation status by FDA and EMA and is heading towards an international Phase III confirmatory study, with a new, IP protected, oral (OATO) formulation. Moderate to Severe forms of Systemic Lupus erythematosus (SLE)^o is another selected target, using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae and the gastro-intestinal tract) in a phase IIa study. Systemic Sclerosis is, in addition, part of the clinical pipeline of BioSenic. Preclinical studies on pertinent animal models are positive. This gives good grounds to launch a Phase II clinical protocol for this serious disease that badly affects skin, lungs or vascularization, and with no actual current effective treatment.*

For further information, please contact:

BioSenic SA

François Rieger, PhD, Chief Executive Officer

Tel: +33 (0)671 73 31 59

investorrelations@biosenic.com

For Belgian Media and Investor Enquiries:

Bepublic

Bert Bouserie

Tel: +32 (0)488 40 44 77

bert.bouserie@bepublicgroup.be

International Media Enquiries:

IB Communications

Neil Hunter / Michelle Boxall

Tel: +44 (0)20 8943 4685

neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:

NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé

Tel: +33 (0)1 44 71 94 94

bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.